anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To provide a system for continuously and industrially producing a peptide having strong function of ACE inhibiting activity from a raw peptide or a protein raw material. CONSTITUTION: A pair of ODS silica gel columns 13 and 130 of the same scale are installed side by side. An adsorption treatment system capable of supplying a raw solution of a peptide for food to both the columns 13 and 130 and adsorbing a peptide substance on the ODS silica gel in the columns 13 and 130 and separating the peptide substance from a filtrate is fixed. A fractionation treatment system capable of feeding ethanol solutions having different concentrations to both the columns 13 and 130 successively stepwise and housing eluted solutions fractionated corresponding to the concentrations of the fed ethanol solutions for each fraction is set. A separation treatment system for separating and recovering ethanol in the eluted solution of the fraction having at least strong function of ACE inhibiting activity from the eluted solutions is laid.  An alternately changing control means for both the columns is installed.
BACKGROUND: Patients with severe chronic obstructive pulmonary disease (COPD) could have palliative care (PC) needs because of unmet needs such as dyspnoea. This may lead to anxiety and may have an impact on patients' ability to perform daily activities of living. PC can be started when patients with COPD have unmet needs and can be provided alongside disease-modifying therapies. Non-invasive ventilation (NIV) could be an important measure to manage dyspnoea in patients with COPD in need of PC. A scoping review was conducted to gain an overview of the existing research and to identify knowledge gaps. The aim of this scoping review was to systematically map published studies on the use of NIV in patients with COPD with PC needs, including the perspectives and experiences of patients, families, and healthcare professionals (HCPs).
METHODS: This review was conducted following the framework of Arksey and O'Malley. The reporting of the review was guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews checklist. The review protocol was published. AMED, CINAHL, Embase, MEDLINE, PEDro, and PsycInfo were searched from inception to November 14, 2022. The included studies had to report the perspectives and experiences of COPD patients, relatives, and HCPs regarding NIV in the care of patients with COPD with PC needs. In pairs, the authors independently assessed studies' eligibility and extracted data. The data were organised thematically. The results were discussed in a consultation exercise.
RESULTS: This review included 33 papers from 32 studies. Four thematic groupings were identified: preferences and attitudes towards the use of NIV; patient participation in the decision-making process of NIV treatment; conflicting results on the perceived benefits and burdens of treatment; and heterogenous clinical outcomes in experimental studies. Patients perceived NIV as a 'life buoy' to keep them alive. Many patients wanted to take part in the decision-making process regarding NIV treatment but expressed varying degrees of inclusion by HCPs in such decision-making. Conflicting findings were identified regarding the perceived benefits and burdens of NIV treatment. Diversity in heterogeneous clinical outcomes were reported in experimental studies.
CONCLUSIONS: There is a need for more studies designed to investigate the effectiveness of NIV as a palliative measure for patients with COPD with PC needs using comprehensive outcomes. It is especially important to gain more knowledge on the experiences of all stakeholders in the use of home-based NIV treatment to these patients.
PURPOSE: An anus cleaning agent composition for pet obtained by adding alcohol, a skin protectant, a carbomer, etc. to purified water and then gelling is provided. The composition has high viscosity and does no flow like liquid and thus causes the user to wipe and clean the surroundings of the anus of a pet with ease by smearing it on bathroom tissue without making fingers dirt. CONSTITUTION: An anus cleaning agent composition for pet comprises 10 to 70% by volume of ethyl alcohol, 5 to 10% by weight of isopropyl alcohol, 0.2 to 0.3% by weight of a carbomer, 0.01 to 0.1% by volume of aminomethyl propanol, 1 to 4% by volume of glycerol, 0.05 to 1% by weight of propylene glycol and 0.1 to 2% by volume of isopropyl myristate. The composition also contains 0.025 to 0.1% by weight of 3-iodo-2-propynyl-butyl-carbamate, 0.05 to 0.25% by weight of methyl-p-hydroxybenzoate, 0.01 to 0.1% by weight of propyl-p-hydroxybenzoate and 0.125 to 2% by weight of sodium propionate alone or in combination thereof. It has a viscosity of 15,000 to 50,000cps and a pH of 5.0 to 7.5.
The participants receive eight weeks of ICBT, based on the treatment manual Unified Protocol by David Barlow and colleagues (2013), with weekly support by a specific therapist that follow the individual participant through all treatment weeks. During the eight weeks, the participant will receive in total eight treatment modules.
FIELD: veterinary science. SUBSTANCE: the suggested innovation deals with medicinal preparations for treating serous mastitis in cows including organic medicinal preparations and solvents. Moreover, as organic medicinal preparations one should apply 1.4-di-N-oxide of 2.3-bis-(oxymethyl)quinoxaline, methyl ether of paraoxybenzoic acid and dimethylsulfoxide, and as polymer-prolongator - propandiol 1.2, moreover, these substances are taken at the following ratio, (%): 1.4-di-N- oxide of 2.3-bis- (oxymethyl)quinoxaline 1.0-1.5, dimethylsulfoxide 5.0-6.5, propandiol 1.2 48.5-50.0, methyl ether of paraoxybenzoic acid 0.5-1.0, distilled water - the rest. The suggested method for treating serous mastitis in cows includes intercysternal introduction of antimastitis preparation and deals with introduction of medicinal preparation into affected portion of cow's udder at the dosage of 5-10 ml once daily for 3 d. Both preparation and method of its application enable to increase economical efficiency of therapy due to decreased labor expenses and financial expenses to purchase medicinal products by 3.5 times, shortened terms of therapy by 1.5 times and increased therapeutic efficiency by 2.7 times. EFFECT: higher efficiency of therapy. 3 cl, 2 ex
Dosage for Hepatically Impaired Patients

The use of sertraline in patients with liver disease should be approached with caution. The effects of sertraline in patients with moderate and severe hepatic impairment have not been studied. If sertraline is administered to patients with liver impairment, a lower or less frequent dose should be used (see CLINICAL PHARMACOLOGYand PRECAUTIONS).

Treatment of Pregnant Women During the Third Trimester

Neonates exposed to sertraline hydrochloride tablets and other SSRIs or SNRIs, late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding (see PRECAUTIONS). When treating pregnant women with sertraline hydrochloride tablets during the third trimester, the physician should carefully consider the potential risks and benefits of treatment. The physician may consider tapering sertraline hydrochloride tablets in the third trimester.
Participates will be randomized to have an 12mm assistant port used during their surgery. The participate will be asked to specify the point that represents their level of perceived pain intensity and mark it on the scale at four time points: baseline pain prior to the procedure in the pre-operatively holding area, 4 to 6 hours post operatively, on Post Operative Day 1 (POD1). The final pain assessment will be at the two weeks postoperative clinic visit.
PROBLEM TO BE SOLVED: To obtain the subject composition capable of suppressing the plaque adherence to an artificial tooth base, excellent in preventing effect of stomatitis due to the artificial tooth, ozostomia, etc., and activating effect of mucous membrane tissue under the artificial tooth base by containing an organic and/or an inorganic bactericide in an artificial tooth stabilizing agent. SOLUTION: This artificial tooth stabilizing agent composition is obtained by blending an organic bactericide (e.g. cetylpyridinium chloride, benzalkonium chloride, benzetonium chloride, triclosan and eugenol) and/or an inorganic bactericide (e.g.; a material obtained by loading silver, copper or zinc on apatite, zeolite, silica, etc.), with an artificial tooth stabilizing agent. The amount of blending is preferably 0.001-5 wt.% (solid portion) based on the total of the composition. Especially, it is possible to further impart a suppressing effect on an endotoxin and an exoteric metabolite produced by bacteria by simultaneously using the cetylpyridinium chloride and the benzetonium chloride or simultaneously using glutamic acid and/or lysozyme with the above two bactericides.
The invention relates to an external medicine for treating psoriasis. The external medicine comprises linoleic acid, oleic acid, palmitic acid, stearic acid, linolenic acid, arachidic acid, morphine, codeine and papaverine. The external medicine has the advantages of stable treatment effect, thorough treatment, no side effects, high application values and high social values when the medicine is used to treat psoriasis. The invention also provides a preparation method of the external medicine. The external medicine is prepared through mixing and heating platn oil and poppy shell. The method has the advantages of simplicity, easy operation, abundant and easily available raw materials, and low cost, and medicine prepared through regulating the raw material ratio, the heating temperature and the heating time has stable and thorough curative effects and high practicality.
PCT No. PCT/FR91/00927 Sec. 371 Date Jul. 16, 1993 Sec. 102(e) Date Jul. 16, 1993 PCT Filed Nov. 22, 1991 PCT Pub. No. WO92/09269 PCT Pub. Date Jun. 11, 1992.Formulations of spiramycin granules may be conducted by preparing a solution of albumin in the presence of an antifoaming agent, separately preparing a suspension of spiramycin in the presence of an antifoaming agent, granulating and drying a mixture of one or more sugars and water, mixing the albumin solution and spiramycin suspension with heating to coagulate the albumin, evaporating the solvents to obtain spiramycin granules, and mixing the sugar granules and spiramycin granules. Oral spiramycin formulations prepared according to this method are also disclosed.
Here, the glycolipopeptide GLIP was obtained by coupling IL-C8 and the monosaccharide molecule D-(+)-glucosamine to the N-terminal and C-terminal of the peptide P, which was designed on the basis of the biological characteristics of the antimicrobial peptides. In vitro bioactivity and physicochemical properties assays confirmed that GLIP had excellent antimicrobial activity against Gram-negative E. coli ATCC 25922 and Gram-positive S. aureus ATCC 29213, as well as good stability in serum and trypsin, low hemolysis, and good bacterial membrane-disrupting ability. In addition, the glycolipopeptide GLIP could self-assembly in aqueous solution to form spherical nano-aggregates, which could encapsulate the small molecule antibiotic TC to form the nanomedicine GLIP@TC and release the TC continuously and slowly in a sustained-release manner, exerting the combined antimicrobial effect of both. The results of animal experiments demonstrated the excellent in vivo antimicrobial activities of GLIP and nanomedicine GLIP@TC. Finally, molecular docking experiment showed that the GLIP could effectively bind to penicillin-binding protein 5 (PBP5) of E. coli and possibly inhibit its D-Ala carboxypeptidase (CPase) activity. All these results may imply the great potential of GLIP for clinical application against bacterial drug resistance.
The present invention relates to a nutrition metabolic acid-base balance regulating agent and a producing technology thereof. The nutrition metabolic acid-base balance regulating agent is composed of the following ingredients according to the weight percentage: 90% to 95% of alfalfa powder, 4% to 9% of green bean powder and 0.5% to 1.5% of polyethylene glycol which is surface active agents. The producing technology of the present invention comprises the following steps: after the alfalfa powder and the green bean powder are proportionally mixed, the alfalfa powder and the green bean powder are uniformly stirred; the mixture is sifted by a mesh screen of 140 meshes; the polyethylene glycol which is the surface active agents is added, the polyethylene glycol and the mixture are uniformly stirred, and the nutrition metabolic acid-base balance regulating agent is prepared. The prepared regulating agent is dried and sterilized, the temperature is 115 to 135 DEG C, and the sterilization time is 1 to 3 mintues. The degree (61.5) of basicity of the alfalfa powder in the acid-base regulating agent of the present invention relates to 4 times higher than that of vegetables with green leaves, such as spinach (15.6), etc. The high degree of basicity of the alfalfa powder is utilized as the acid-base balance regulating agent to regulate a metabolic process of a human body. In addition, the present invention has high content of cellulose, which is good for accelerating the elimination of acid material of the human body, and is beneficial to the health of the human body.
and oligo-tartaric acids (I) and their salts are obtd. by heating tartaric acid of formula (II), removing the water of reaction, and opt. neutralising the prod. with a base. Also claimed is a surfactant compsn. comprising (I) and anionic, nonionic, cationic and/or amphoteric or zwitterionic tensides. (I) are useful as complexing agents in surfactants used in liq. or powder universal or delicate washing compsns., manual dishwashing compsns., rinses, liq. cleaning and disinfecting compsns., hair shampoos and rinses, and bath foams. (I) are biodegradable and dispersible or soluble in cold water. (I) have good complexing capacity for 2- or more valent metal cations, and is similar to that of known complexing agents for washing compsns.
Teratogenic Effects:

Pregnancy category B. After oral administration, famciclovir (prodrug) is converted to penciclovir (active drug). There are no adequate and well-controlled studies of famciclovir or penciclovir use in pregnant women. No adverse effects on embryofetal development were observed in animal reproduction studies using famciclovir and penciclovir at doses higher than the maximum recommended human dose (MRHD) and human exposure. Because animal reproduction studies are not always predictive of human response, famciclovir should be used during pregnancy only if needed.

In animal reproduction studies, pregnant rats and rabbits received oral famciclovir at doses (up to 1000 mg/kg/day) that provided 2.7 to 10.8 times (rats) and 1.4 to 5.4 times (rabbits) the human systemic exposure based on AUC. No adverse effects were observed on embryo-fetal development. In other studies, pregnant rats and rabbits received intravenous famciclovir at doses (360 mg/kg/day) 1.5 to 6 times (rats) and (120 mg/kg/day) 1.1 to 4.5 times (rabbits) or penciclovir at doses (80 mg/kg/day) 0.3 to 1.3 times (rats) and (60 mg/kg/day) 0.5 to 2.1 times (rabbits) the MRHD based on body surface area comparisons. No adverse effects were observed on embryo-fetal development.
Up to 600 male and female healthcare personnel ages 18 years and older in Tshuapa Province in The Democratic Republic of Congo at risk for mpox will receive two doses of attenuated live virus smallpox vaccine (JYNNEOS lyophilized formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 10\^8 Tissue Culture Infectious Dose 50 \[TCID50\] per 0.5 mL). A subset of participants will receive a booster dose.
Our understanding of hereditary breast and ovarian cancer has significantly improved over the past two decades. In addition to BRCA1/2, pathogenic variants in several other DNA-repair genes have been shown to increase the risks of breast and ovarian cancer. The magnitude of cancer risk is impacted not only by the gene involved, but also by family history of cancer, polygenic risk scores, and, in certain genes, pathogenic variant type or location. While estimates of breast and ovarian cancer risk associated with pathogenic variants are available, these are predominantly based on studies of high-risk populations with young age at diagnosis of cancer, multiple primary cancers, or family history of cancer. More recently, breast cancer risk for germline pathogenic variant carriers has been estimated from population-based studies. Here, we provide a review of the field of germline genetic testing and risk evaluation for hereditary breast and ovarian cancers in high-risk and population-based settings.
Heat and/or foam is produced in cosmetics by the reaction of an oxidiser (pref. H2O2) with a reducer (pref. ascorbic acid) in the presence of a catalyst (pref. CuSO4) and a neutralising agent (pref. a(Bi)carbonate). The product is pref. packed into two separate compartments which are mixed on use. They are used in self-heating shaving creams, shampoos massage creams and depilatories. The components are non-toxic odourless and non-discolouring.
An image processing and handling system is provided for the efficient combination of image data from multiple sources and of different types. The system includes an image processing device having an electronic control unit (ECU) that receives a first set of image data from an image data provider such as a PACS server over a telecommunications network. The first set of image data includes image pixel data from a first image of a physical structure in a living being and may be obtained from a DICOM compatible file. The ECU is further configured to combine the first set of image data with a second set of image data to form a combined set of image data. The second and combined sets of image data may each include pixel data for second and combined images, respectively of the physical structure. The ECU is further configured to transmit the combined set of image data to a remote computing device over a second telecommunications network
Spinal anesthesia in the cesarean section often causes significant peripheral vascular dilatation, decreases blood pressure and cardiac output reduction which leads to maternal nausea, vomiting, dizziness and uteroplacental hypoperfusion. Infusion therapy and the use of vasopressor can prevent and treat the incidence of hypotension. Appropriate fluid therapy can not only maintain maternal tissue perfusion, but also reduce uteroplacental hypoperfusion. In the present study, perioperative goal directed fluid therapy is used. The non-invasive continuous hemodynamic monitor is used in this study, and the parameters (blood pressure (BP), stroke volume(SV), stroke volume variation (SVV), cardiac output (CO)) are used to determine the parameters of the blood transfusion in cesarean section as infusion guidelines. The application of Clearsight system to the pre-infusion of target-guided crystalloid solution is compared with the infusion of quantitative crystalline solution in the hope of reducing the incidence of maternal hypotension, reducing the use of vasopressin, improving uteroplacental perfusion and reducing the incidence of fetal acidosis.
In the central nervous system (CNS), a large group of glial cells called astrocytes play important roles in both physiological and disease conditions. Astrocytes participate in the formation of neurovascular units and interact closely with other cells of the CNS, such as microglia and neurons. Stroke is a global disease with high mortality and disability rate, most of which are ischemic stroke. Significant strides in understanding astrocytes have been made over the past few decades. Astrocytes respond strongly to ischemic stroke through a process known as activation or reactivity. Given the important role played by reactive astrocytes (RAs) in different spatial and temporal aspects of ischemic stroke, there is a growing interest in the potential therapeutic role of astrocytes. Currently, interventions targeting astrocytes, such as mediating astrocyte polarization, reducing edema, regulating glial scar formation, and reprogramming astrocytes, have been proven in modulating the progression of ischemic stroke. The aforementioned potential interventions on astrocytes and the crosstalk between astrocytes and other cells of the CNS will be summarized in this review.
Intervention foreseen is scheduled radiologic evaluations (CT or MRI scan) and PET scan if patients ≥ 50 years old and with a smoking history ≥ 20 pack year. Follow up outpatient visits will be performed similarly to ARM A, including physical and fiberoptic endoscopic head and neck evaluation and laboratory tests and questionnaires. Locoregional imaging will be requested for all the patients 2 times/year in the first 2 years and 1 time/year in the third and fourth year; PET scan will be requested yearly in the first 3 years. In the first year after RT end, MRI or CT scan will be performed at screening and at sixth month after enrollment, while PET scan will be performed six months after enrollment only in patients ≥50 years and with a smoking history of ≥20 pack/years.
PURPOSE:A food, containing dried powder and/or extract and/or extract powder of the leaf part of Japanese radish as an active constituent, and capable of improving scoliosis or bad postural habit which is a prodromic form thereof. CONSTITUTION:A posture orthotic food containing dried powder and/or extract and/or extract powder of the leaf part of Japanese radish as an essential component. The leaf of the Japanese radish contains Ca, particularly Ca components which can be easily taken and excellent for increase in blood Ca concentration together with other components particularly vitamin K, are believed to bond to amino acids contained in rice brewed vinegar KOJI or SAKE KOJI incorporated if necessary to promote absorption and metabolism in muscles. Thus, the reinforcing muscle around the backbone is first strengthened, resulting in gradual orthosis of abnormality in bones, e.g. scoliosis, etc. Any food form may be taken as the posture orthotic food, and the intake amount thereof is about 1,000-10,000mg for adults and about 2/3 for children and aboud 1/3 for infants based on the above-mentioned amount for the adults.
The present invention is for a device and a gel method for controlling pH by acidic buffering. The device is made of a flexible dome, a flexible circular rim and an absorbent acidic buffer. The flexible dome is attached at its margin to the circular rim and the absorbent acidic buffer is contained within the device. The absorbent acidic buffer can control or maintain pH within physiological ranges. The gel method for controlling pH by acidic buffering is accomplished by applying a gel to an area where the pH is to be controlled. The gel includes an acidic buffering polymer which can control or maintain the pH of the area within the range of about 3 to about 5.
Drugs that interfere with serotonin reuptake, including FETZIMA, may increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Based on data from the published observational studies, exposure to SNRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage [see Use in Specific Populations (8.1)]. Bleeding events related to SSRIs and SNRIs have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages. 

Inform patients about the increased risk of bleeding associated with the concomitant use of FETZIMA and NSAIDs, aspirin, or other drugs that affect coagulation [see Drug Interactions (7.1)].